ArticleBMC microbiology2026
Molecular analysis of polymyxin B resistance in clinical carbapenem-resistant Klebsiella pneumoniae isolates from a large tertiary care teaching hospital in Southwest China.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to investigate the molecular basis of polymyxin B resistance in clinical carbapenem-resistant Klebsiella pneumoniae (CRKP) isolates.
methodsA total of 52 polymyxin B-resistant CRKP clinical isolates were collected at West China Hospital between 2018 and 2021. Polymyxin B susceptibility testing was performed using the broth microdilution method. Whole-genome sequencing was conducted to determine sequence types (STs), capsular loci, resistance genes, virulence genes and mutations in genes associated with polymyxin B resistance. Transcriptome sequencing was used to compare changes in gene expression between selected high-minimum inhibitory concentration (MIC) isolates after polymyxin B exposure and controls cultured without polymyxin B.
resultsThe majority (98.08%, 51/52) of CRKP isolates produced carbapenemases, predominantly KPC-2 (92.16%, 47/51). ST11 (88.46%, 46/52) and capsular type KL64 (71.15%, 37/52) were the most prevalent. Eleven isolates (21.15%) were found to carry genetic markers associated with hypervirulence, including rmpA, rmpA2, iucABCD, iutA and peg-344. Genetic alterations in the mgrB gene were identified in 80.77% (42/52) of the polymyxin B- resistant isolates. These alterations were primarily mediated by insertion sequences (88.10%, 37/42), with IS5 family elements being the most common. Isolates with mgrB alterations exhibited significantly higher polymyxin B MICs (geometric mean 28.51 mg/L, MIC₅₀ 32 mg/L, MIC₉₀ 64 mg/L) than those without (geometric mean 11.31 mg/L, MIC₅₀ 12 mg/L, MIC₉₀ 32 mg/L) (P = 0.003). Several amino acid substitutions were identified in polymyxin B resistance-related proteins, including D86E, E57G, and A41T in PmrA; G345E, T157P, and L213M in PmrB; D191A in PhoP; A63E and A20S in PhoQ; and S257L and M54I in PmrC. Notably, some mutations, such as M54I in PmrC and A20S and A63E in PhoQ, have not been previously reported. No mcr genes were detected. Transcriptomic analysis of isolates P40 (MIC > 64 mg/L) revealed upregulation of pmrA (log₂FC = 1.02, adjusted P < 0.001), but downregulation of ompA (log₂FC = -2.85), arnA (log₂FC = -1.46), ugd (log₂FC = -1.01) and tolC (log₂FC = -1.66) (adjusted P < 0.001 for all) after polymyxin B exposure.
conclusionsIn southwest China, polymyxin B resistance in the studied CRKP isolates was most frequently associated with chromosomal mutations, particularly insertional inactivation of the mgrB gene. The emergence of polymyxin B- and carbapenem-resistant ST11-KL64 hypervirulent clone is a potential threat to antiinfection treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.